All In MedTech

Device Trial Radar · NCT02516228

Transcranial Electrical Neuromodulation for Suppressing Epileptiform Discharges

Geodesic Transcranial Electrical Neuromodulation(GTEN100) Device

Last checked: Nov 19, 2026Latest source record: Jul 22, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

6

Actual

Start

Aug 2016

Primary completion

May 2018

Study completion May 2018

Sponsor

Lead sponsor
Electrical Geodesics, Inc.Not on our public-company list
Sponsor type
Industry
Collaborators
Harborview Injury Prevention and Research Center
First posted
Aug 5, 2015

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 14 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study examines the safety and feasibility of suppressing epileptic discharges through inducing long term depression of the epileptic focus with transcranial electrical neuromodulation.

Conditions

  • Epilepsy

Interventions

  • GTEN 100Device

    Stimulation will be focused on the seizure generating cortex. All patients enrolled in the study will have a pre-treatment baseline evaluation period. During this time, the patient (and/or family) will maintain the seizure diary that simply tracks the number of seizure the patient experiences each day. During this baseline period, two two-hour EEG recordings (to be completed on 2 separate days) will be acquired. This baseline EEG data will be used to establish baseline inter-ictal spike rate as well as classification of the inter-ictal spikes used to localize seizure onset zone. Using the localization information, patients will be treated with the device for five concurrent days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Number of Spikes Per HourTime frame: Baseline and following the 5 day treatment session

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Harborview Medical Center - University of Washington

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.